ClinicalTrials.gg
CompletedNCT03032510IGNITE3Updated Jan 6, 2022Results posted

Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections

A Phase 3 interventional study of Eravacycline and Ertapenem in Complicated Urinary Tract Infections, sponsored by Tetraphase Pharmaceuticals, Inc.. Completed at 71 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-06.

Sponsored by Tetraphase Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,205
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Urinary Tract Infections with a site in Ukraine — none open to participants now, none under way, none of them phase 3. Urinary Tract Infections · Ukraine.

Enrollment
2nd of 11
1,205 · median 598
Started
2017
with 1 other
Phase 3
9 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Tetraphase Pharmaceuticals, Inc.

Among the 11 studies in Urinary Tract Infections with a site in Ukraine, this one is the 2nd largest by enrollment, is one of 2 that started in 2017, is one of 9 in phase 3, and was the 7th registered.

Urinary Tract Infections

804 studies on the registry are indexed under Urinary Tract Infections; 133 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

None of the 11 studies in Urinary Tract Infections with a site in Ukraine is open now. The open studies under Urinary Tract Infections, anywhere →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 50 (60%) set no upper age limit and 23 (27%) stop at 75 or younger; 15 take children under 18; 17 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Urinary Tract Infections with a site in Ukraine as a file.
02

Study summary

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

Read the detailed description

The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of eravacycline compared to ertapenem in treating participants with complicated urinary tract infections (cUTI).

This is a phase 3, randomized, double-blind, double-dummy, multicenter, prospective study to assess the efficacy, safety and pharmacokinetics of eravacycline compared with ertapenem in the treatment of cUTI.

Randomization will be stratified based on two criteria: (1) by primary site of infection (pyelonephritis and normal urinary tract anatomy vs all other diagnoses) and (2) by the receipt of a single dose of effective non-study antibiotics for the acute cUTI within 72 hours prior to randomization. An enrollment cap of approximately 50% is planned for subjects with pyelonephritis with normal urinary tract anatomy. Also, an enrollment cap of approximately 20% is planned for subjects who have received a single dose of non-study antibiotics for the acute cUTI within 72 hours prior to randomization.

In this study subjects will be enrolled and randomized to one of two treatment arms in a 1:1 ratio: (i) eravacycline intravenously (IV) / levofloxacin (PO), or (ii) ertapenem (IV) / levofloxacin (PO).

03

Conditions studied

  • Complicated Urinary Tract Infections
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participant with either:

    1. Pyelonephritis and normal urinary tract anatomy (approximately 50% of the total population), or
    2. cUTI with at least one of the following conditions associated with a risk for developing cUTI:

      • Indwelling urinary catheter
      • Urinary retention (at least approximately 100 milliliters (mL) of residual urine after voiding)
      • History of neurogenic bladder
      • Partial obstructive uropathy (for example, nephrolithiasis, bladder stones, and ureteral strictures)
      • Azotemia of renal origin (not congestive heart failure [CHF] or volume related) such that the serum blood urea nitrogen [BUN] is elevated (>20 milligrams [mg]/deciliters [dL]) and the serum BUN:creatinine ratio is \<15
      • Surgically modified or abnormal urinary tract anatomy (for example, bladder diverticula, redundant urine collection system) except urinary tract surgery within the last 30 days (placing of stents or catheters is not considered to be surgical modification)
  2. At least 18 years of age at time of consent
  3. Able to provide
  4. At least two of the following signs or symptoms:

    1. Chills, rigors, or warmth associated with fever or hypothermia
    2. Flank pain (pyelonephritis) or pelvic pain (cUTI)
    3. Nausea or vomiting
    4. Dysuria, urinary frequency, or urinary urgency
    5. Costo-vertebral angle tenderness on physical examination
  5. Urine specimen with evidence of pyuria

    1. Dipstick analysis positive for leukocyte esterase (where positive result is at least "++" as indicated on the urine dipstick provided in the laboratory kit), or
    2. ≥10 white blood cells (WBCs) per cubic millimeter, or
    3. ≥10 WBCs per high power field
  6. If male: must agree to use an effective barrier method of (for example, condom) during the study and for 14 days following the last dose if sexually active with a female of
  7. If female, not pregnant or nursing or, if of childbearing potential: must commit to either use at least two medically accepted, effective methods of birth control (for example, condom, spermicidal gel, oral contraceptive, indwelling intrauterine device, hormonal implant /patch, injections, approved cervical ring) during study drug dosing and for 14 days following last study drug dose or practicing sexual abstinence

Exclusion criteria

Exclusion Criteria:

  1. Use of systemic antibiotics effective in cUTI within 72 hours prior to enrollment except under the following circumstances:

    1. Participants with suspected acute cUTI who have received a single dose of effective non-study antibiotics for the acute cUTI
    2. Signs and symptoms of cUTI developed while on the antibiotic for another indication
  2. History of an ertapenem-resistant urinary tract infection within 1 year of enrollment
  3. Likely to require >10 days of antibiotic treatment to cure the acute cUTI or likely to receive ongoing antibacterial drug prophylaxis prior to the Follow Up visit (21-28 days after randomization) [for example, participants with chronic vesiculo-ureteral reflux]
  4. Unlikely to survive at least through the duration of the study
  5. Hypotension, systolic blood pressure ≤90 millimeters of mercury [mmHg]
  6. Complicated pyelonephritis with complete obstruction or known or suspected renal or perinephric abscess, emphysematous pyelonephritis, or Any condition likely to require surgery to achieve cure (this does not include procedure to place catheters or obtain diagnosis)
  7. Known or suspected urinary fungal infection
  8. Uncomplicated lower urinary tract infections
  9. Suspected or confirmed active prostatitis, or currently under treatment for prostatitis
  10. High risk for cUTI due to Pseudomonas (for example, history of prior cUTIs due to Pseudomonas, ≥20 mg once a day prednisone or equivalent , and other risk factors as perceived by the Investigator)
  11. History of renal transplantation
  12. Presence of an ileal loop
  13. Any history of trauma to the pelvis or urinary tract occurring within 30 days of screening
  14. Indwelling urinary catheters present at screening which are not expected to be removed or replaced within 72 hours of enrollment (for example, nephrostomy tubes, stents, urethral and suprapubic catheters).
  15. Known concomitant (HIV) infection with below 200 within the last six months, or an acquired immune deficiency syndrome (AIDS) defining diagnosis within the last six months
  16. Neutropenia ( \<1,000 polymorphonuclear leukocytes [PMNs]/microliters [µL])
  17. Participation in a study with an experimental drug or device within 30 days prior to enrollment
  18. Known or suspected to tetracyclines, carbapenems, or β-lactams
  19. History of seizures
  20. Any other unstable or concurrent medical condition (for example, therapy, chemotherapy, class IV heart or lung disease, end stage renal disease, or requiring hemodialysis) that would, in the opinion of the Investigator, jeopardize the safety of a participant and/or their compliance with the protocol
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,205 participants (actual)

Study arms

  • Experimental
    Eravacycline (Intravenous)/Levofloxacin (Oral)

    Drug: Eravacycline · Drug: Placebo · Drug: Levofloxacin

  • Active comparator
    Ertapenem (Intravenous)/Levofloxacin (Oral)

    Drug: Ertapenem · Drug: Placebo · Drug: Levofloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit

    This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.

    Time frame: End of Infusion

  2. Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit

    This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.

    Time frame: TOC visit (14-17 days after randomization)

Secondary outcomes

  1. Proportion of Participants in the ITT Population With Favorable Clinical Outcomes at TOC Visit

    Clinical cure: A complete resolution or significant improvement of signs or symptoms of the infection such that no rescue/non-study antibacterial medication was required to treat the cUTI that presented at study entry. Clinical failure: Subjects were classified as clinical failure in the event of * Death related to cUTI at any timepoint * Persistence of clinical symptoms of cUTI or new symptoms developed * Initiation of rescue/non-study antibacterial medication for cUTI Indeterminate: Study data were listed as indeterminate if the outcome was other than clinical cure or clinical failure. The reason for an indeterminate designation had to be provided Missing: Study data were listed as missing if the Investigator did not complete an assessment or if the subject did not complete the study visit.

    Time frame: TOC visit (14-17 days after randomization)

07

Results

Posted Oct 2, 2019

Participant flow

Participant flow — Overall Study
MilestoneEravacycline (Intravenous)/Levofloxacin (Oral)Ertapenem (Intravenous)/Levofloxacin (Oral)
Started603602
Completed576584
Not completed2718
Withdrew: Adverse event52
Withdrew: Lost to follow-up87
Withdrew: Withdrawal by subject87
Withdrew: Subject noncompliance42
Withdrew: Physician decision20

Outcome measures

PrimaryProportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit

This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of Responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.

Time frame:
End of Infusion
Reported as:
Count of participants · Participants
Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the EOI Visit
ParticipantsEravacycline (Intravenous)Ertapenem (Intravenous)
Responder363382
Non-responder517
Indeterminate1414
PrimaryProportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit

This was the co-primary outcome measure for the Food and Drug Administration (FDA). The primary objective was to demonstrate the non-inferiority (NI) of eravacycline to ertapenem in responder outcome, which was derived from both clinical and microbiological responses, in the micro-ITT population. Clinical responses were either cure, failure, or indeterminate/missing; microbiological responses were characterized programmatically as either success, failure, or indeterminate/missing. Clinical cure was defined as complete resolution or significant improvement of signs or symptoms of the infection; microbiological success was a reduction of the baseline pathogen(s) to \<10\^4 colony-forming units/milliliter (CFU/mL). An outcome of responder required a clinical response of cure and a microbiological response of success. Any other combination of the clinical and microbiological responses was considered either Non-responder or Indeterminate.

Time frame:
TOC visit (14-17 days after randomization)
Reported as:
Count of participants · Participants
Proportion of Participants in the Micro-ITT Population Demonstrating Clinical Cure and Microbiologic Success at the Test-Of-Cure (TOC) Visit
ParticipantsEravacyclineErtapenem
Responder293302
Non-responder11686
Indeterminate1915
SecondaryProportion of Participants in the ITT Population With Favorable Clinical Outcomes at TOC Visit

Clinical cure: A complete resolution or significant improvement of signs or symptoms of the infection such that no rescue/non-study antibacterial medication was required to treat the cUTI that presented at study entry. Clinical failure: Subjects were classified as clinical failure in the event of * Death related to cUTI at any timepoint * Persistence of clinical symptoms of cUTI or new symptoms developed * Initiation of rescue/non-study antibacterial medication for cUTI Indeterminate: Study data were listed as indeterminate if the outcome was other than clinical cure or clinical failure. The reason for an indeterminate designation had to be provided Missing: Study data were listed as missing if the Investigator did not complete an assessment or if the subject did not complete the study visit.

Time frame:
TOC visit (14-17 days after randomization)
Reported as:
Count of participants · Participants
Proportion of Participants in the ITT Population With Favorable Clinical Outcomes at TOC Visit
ParticipantsEravacycline (Intravenous)/Levofloxacin (Oral)Ertapenem (Intravenous)/Levofloxacin (Oral)
Clinical Cure547566
Clinical Failure3120
Indeterminate/missing2516

Adverse events

Collected over The time frame for adverse event reporting was from the first dose of study drug through 30 days after the last dose of study drug or the FU visit (whichever was later).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eravacycline (Intravenous)3/601 (0.5%)11/601 (1.8%)174/601 (29%)
Ertapenem (Intravenous)2/600 (0.3%)6/600 (1%)52/600 (8.7%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventEravacycline (Intravenous)Ertapenem (Intravenous)
Cerebrovascular accidentNervous system disorders2/6010/600
Aneurysm rupturedVascular disorders2/6011/600
Cardiorenal syndromeCardiac disorders0/6011/600
HaemorrhoidsGastrointestinal disorders0/6011/600
Clostridium difficile colitisInfections and infestations0/6011/600
Renal abscessInfections and infestations0/6011/600
MeningiomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/6011/600
Circulatory collapseVascular disorders0/6011/600
Acute myocardial infarctionCardiac disorders1/6010/600
Myocardial infarctionCardiac disorders1/6010/600
Most frequent other events
Most frequent other events
EventEravacycline (Intravenous)Ertapenem (Intravenous)
NauseaGastrointestinal disorders84/60110/600
VomitingGastrointestinal disorders31/6014/600
Infusion site phlebitisGeneral disorders24/6013/600
HeadacheGeneral disorders17/60118/600
DiarrhoeaGastrointestinal disorders18/60117/600

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Eravacycline (Intravenous)/Levofloxacin (Oral)Ertapenem (Intravenous)/Levofloxacin (Oral)Total
<=18 years000
Between 18 and 65 years338331669
>=65 years265271536
Age, Continuous
Age, Continuous(years)Eravacycline (Intravenous)/Levofloxacin (Oral)Ertapenem (Intravenous)/Levofloxacin (Oral)Total
Mean57.1 ± 18.1656.5 ± 19.3456.8 ± 18.7
Sex: Female, Male
Sex: Female, Male(Participants)Eravacycline (Intravenous)/Levofloxacin (Oral)Ertapenem (Intravenous)/Levofloxacin (Oral)Total
Female330343673
Male273259532
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Eravacycline (Intravenous)/Levofloxacin (Oral)Ertapenem (Intravenous)/Levofloxacin (Oral)Total
Hispanic or Latino111526
Not Hispanic or Latino5925871179
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Eravacycline (Intravenous)/Levofloxacin (Oral)Ertapenem (Intravenous)/Levofloxacin (Oral)Total
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American213
White6006011201
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Eravacycline (Intravenous)/Levofloxacin (Oral)Ertapenem (Intravenous)/Levofloxacin (Oral)Total
Latvia363975
Austria011
Romania5459113
Hungary5666122
United States91322
Ukraine148137285
Georgia334073
Slovakia181331
Bulgaria6142103
Estonia212041
Russia126143269
Poland231740
Moldova181230
08

Study locations

71 sites
  • Fullerton, California, United States
  • Los Angeles, California, United States
  • Torrance, California, United States
  • Coral Gables, Florida, United States
  • Doral, Florida, United States
  • Miami, Florida, United States
  • Columbus, Georgia 31820, United States
  • Saint Louis, Missouri, United States
  • Las Vegas, Nevada, United States
  • Baytown, Texas, United States
  • Graz, Austria
  • Linz, Austria
  • Salzburg, Austria
  • Pleven, Bulgaria
  • Plovdiv, Bulgaria
  • Razgrad, Bulgaria
  • Ruse, Bulgaria
  • Smyadovo, Bulgaria
  • Sofia, Bulgaria
  • Varna, Bulgaria
  • Veliko Tarnovo, Bulgaria
  • Tallinn, Estonia
  • Tartu, Estonia
  • Voru, Estonia
  • K'ut'aisi, Georgia
  • T'bilisi, Georgia
  • Baja, Hungary
  • Budapest, Hungary
  • Miskolc, Hungary
  • Nagykanizsa, Hungary
  • Nyiregyhaza, Hungary
  • Sopron, Hungary
  • Szentes, Hungary
  • Tatabanya, Hungary
  • Jelgava, Latvia
  • Riga, Latvia
  • Valmiera, Latvia
  • Chisinau, Moldova, Republic of
  • Braşov, Romania
  • Bucharest, Romania
  • Craiova, Romania
  • Oradea, Romania
  • Arkhangel'sk, Russian Federation
  • Moscow, Russian Federation
  • Pyatigorsk, Russian Federation
  • Rostov-on-the-Don, Russian Federation
  • Saint Petersburg, Russian Federation
  • Smolensk, Russian Federation
  • Vsevolozhsk, Russian Federation
  • Yaroslavl', Russian Federation
  • Nitra, Slovakia
  • Poprad, Slovakia
  • Presov, Slovakia
  • Svidnik, Slovakia
  • Zilina, Slovakia
  • Chernihiv, Ukraine
  • Chernivtsi, Ukraine
  • Dnipro, Ukraine
  • Ivano-Frankivsk, Ukraine
  • Kharkiv, Ukraine
  • Kyiv, Ukraine
  • L'viv, Ukraine
  • Lviv, Ukraine
  • Mykolaiv, Ukraine
  • Odesa, Ukraine
  • Poltava, Ukraine
  • Uzhgorod, Ukraine
  • Uzhorod, Ukraine
  • Vinnytsya, Ukraine
  • Zaporizhia, Ukraine
  • Zhytomyr, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2017 to primary completion in Dec 2017, 11 months.

Results were first posted in Oct 2019, 1 year 10 months after primary completion.

Of 23 industry-sponsored phase 3 interventional studies under Urinary Tract Infections, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 28. This study's 11 months is below that.

Counting every sponsor, half of 37 studies reached it within 20 months; a quarter within 14 and three quarters within 32.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2017
First posted
Jan 26, 2017
StartActual
Jan 2017
Primary completionActual
Dec 2017
CompletionActual
Jan 2018
Results first posted
Oct 2, 2019
Last update
Jan 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03032510
Lead sponsor
Tetraphase Pharmaceuticals, Inc.
Responsible party
Sponsor
First posted
Jan 26, 2017
Start date
Jan 2017
Primary completion
Dec 2017
Completion
Jan 2018
Results posted
Oct 2, 2019
Last update
Jan 6, 2022

Study contacts

Chief Medical Officer
study director · Tetraphase Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Eravacycline

Start the discussion